Highlights Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Market Closed - OTC Markets Other stock markets 12:24:07 16/05/2024 am IST			5-day change	1st Jan Change
0.0551 ^USD	-8.17%		-2.48%	-21.40%

2023	Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	04/11	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301	18/23/18	CI
Aridisâ€™ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDAâ€™s Qualified Infectious Diseases Product Designation	12/23/12	CI
Aridis Pharmaceuticals' AR-301 Eligible for Consideration Under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs	20/23/20	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Aridis Pharmaceuticals, Inc. Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design	31/23/31	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI
Aridis Pharmaceuticals, Inc. Terminates License, Development and Commercialization Agreement with Serum	10/23/10	CI
Aridis Pharmaceuticals, Inc. Meets Primary and Secondary Endpoints in Phase 2A Study of AR-501 in Cystic Fibrosis Patients	13/23/13	CI
Aridis Pharmaceuticals, Inc. Announces Top-Line Results from the AR-301-002 Phase 3 Study	26/23/26	CI
Aridis Pharmaceuticals, Inc. Announces New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update	18/23/18	CI
Aridis Pharmaceuticals Says Cystic Fibrosis Foundation Invests $4.85 Million; Shares Rise	12/22/12	MT
Aridis Pharmaceuticals, Mapp Biopharmaceutical Sign Deal for Rights to Anti-Ebola, Anti-Marburg Therapeutics Development	05/22/05	MT
Aridis Pharmaceuticals, Inc. Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical	05/22/05	CI
Aridis Announces A Key Milestone of Closing of Patient Enrollment in the Phase 2A Study of AR-501 in Cystic Fibrosis Patients	30/22/30	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/22/22	CI
Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study	04/22/04	CI
Aridis Pharmaceuticals Q2 Loss Narrows	17/22/17	MT
Earnings Flash (ARDS) ARIDIS PHARMACEUTICALS Posts Q2 Revenue $292,000	17/22/17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Highlights

Filters